Everything below concerns Carcinogenicity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-27. Numbers and descriptions here follow the published literature rather than marketing material.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Magnesium is often used to ignite thermite or other materials that require a high ignition temperature. Magnesium continues to be used as an incendiary element in warfare. Flame temperatures of magnesium and magnesium alloys can reach 3,100 °C (5,610 °F), although flame height above the burning metal is usually less than 300 mm (12 in). Once ignited, such fires are difficult to extinguish because they resist several substances commonly used to put out fires; combustion continues in nitrogen (forming magnesium nitride), in carbon dioxide (forming magnesium oxide and carbon), and in water (forming magnesium oxide and hydrogen, which also combusts due to heat in the presence of additional oxygen).
=== Pharmacokinetics === Gepotidacin is rapidly absorbed orally, reaching peak plasma concentrations (tmax) after approximately 2.0 hours. In adults with uncomplicated urinary tract infections (uUTI) and normal renal function, the mean steady-state maximum concentration (Cmax) is 4.2 mcg/mL, and the area under the concentration-time curve over 12 hours AUC(0-12) is 22.8 mcg*hour/mL following a 1500 mg dose every 12 hours. Systemic exposure (Cmax and AUC) increases proportionally with dose. Accumulation of approximately 40% occurs and achieves a steady state by day 3. The absolute bioavailability is about 45%, and standard and moderate fat meals did not significantly affect its absorption. Gepotidacin's pharmacokinetics were found to be generally consistent across different ages, sexes, races, and body weights during modeling and simulation. Gepotidacin has a mean steady-state volume of distribution (Vss) of 172.9 liters and is 25-41% bound to plasma proteins. It has a terminal elimination half-life of approximately 9.3 hours and a total clearance of 33.4 L/hour. The primary metabolic pathway involves CYP3A4, with a minor metabolite (M4, ~11% of circulating drug). The co-administration of other drugs can influence gepotidacin levels. Strong inhibitors of CYP3A4 can increase gepotidacin exposure, whereas strong inducers of CYP3A4 can decrease it. Additionally, gepotidacin, at high concentrations, has shown the potential to increase the exposure of certain other drugs, including digoxin and midazolam.
=== Affordable Care Act === Schmitt filed lawsuits to have the Affordable Care Act invalidated by courts. After Missouri voters approved a constitutional amendment to expand Medicaid coverage in the state, he argued that Republican lawmakers and Governor Mike Parson could legally refuse to implement the expansion. The Missouri Supreme Court rejected that position in a 2021 ruling.
Sources: en.wikipedia.org
Loss-of-function mutations, also called inactivating mutations, result in the gene product having less or no function (being partially or wholly inactivated). When the allele has a complete loss of function (null allele), it is often called an amorph or amorphic mutation in Muller's morphs schema. Phenotypes associated with such mutations are most often recessive. Exceptions are when the organism is haploid, or when the reduced dosage of a normal gene product is not enough for a normal phenotype (this is called haploinsufficiency). Examples of diseases caused by a loss-of-function mutation include Gitelman syndrome and cystic fibrosis. Gain-of-function mutations also called activating mutations, change the gene product such that its effect gets stronger (enhanced activation) or even is superseded by a different and abnormal function. When the new allele is created, a heterozygote containing the newly created allele as well as the original will express the new allele; genetically this defines the mutations as dominant phenotypes. Several of Muller's morphs correspond to the gain of function, including hypermorph (increased gene expression) and neomorph (novel function). Dominant negative mutations (also called anti-morphic mutations) have an altered gene product that acts antagonistically to the wild-type allele. These mutations usually result in an altered molecular function (often inactive) and are characterized by a dominant or semi-dominant phenotype.
Research and development as well as production, however, remain at the Herisau site. Metrohm AG moved from the town center of Herisau in 2011 to its new premises in the industrial zone "Hölzli". The new premises were expanded in 2015 to accommodate the growing number of employees. In summer 2024, Metrohm expanded its Herisau campus by an additional 20,000 square meters. In 2025, Metrohm established new subsidiaries in Korea, Portugal and Ghana.
=== Post-AFL career === In 2013, Prismall joined the Western Bulldogs. On-field, he played in 2013 for the Bulldogs' VFL affiliate, the Williamstown Seagulls; then, in 2014, when the Bulldogs ended their affiliation with Williamstown, began playing for the club's new reserves team in the VFL. He served in other roles at the football club, including as a runner and as player welfare manager. Prismall, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 VFL season and was forced to stand down from his role as player welfare manager. After 13 years working in player welfare at the Bulldogs, Prismall returned to Essendon ahead of the 2027 AFL season as the club's Head of Development.
In 2008, Calderón signed the Mérida Initiative with the United States, which provided funding, training, and intelligence, and allowed U.S. personnel to operate in Mexico in advisory and intelligence-sharing capacities. By 2011, the Mexican Armed Forces had captured 11,544 people who were believed to have been involved with the cartels and organized crime. In the year prior, 28,000 individuals were arrested on drug-related charges. In October 2012, Mexican Navy forces killed Heriberto Lazcano, leader of Los Zetas, in a shootout in Sabinas, Coahuila, after gunmen attacked their patrol. The operation came just hours after the capture of another senior Zeta, Salvador Alfonso Martínez Escobedo. Lazcano's death is viewed as the most significant cartel leader killing in Calderón's administration. It strengthened the Navy's standing, allowed Miguel Treviño Morales to take control of Los Zetas, and ultimately benefited Joaquín "El Chapo" Guzmán, whose Sinaloa Cartel sought to dominate the Nuevo Laredo smuggling routes.
Sources: en.wikipedia.org
Phenotypes of overlap between Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy can be assumed. In the differential diagnosis of UCDM, even in patients without finger contractures, Bethlem myopathy could be considered.
=== Texas research initiative === In 2025, the state of Texas allocated $50 million to fund clinical research on ibogaine, aiming to develop a U.S. Food and Drug Administration-approved treatment for opioid use disorder, co-occurring substance use disorders, and other ibogaine-responsive conditions. The initiative, supported by former Governor Rick Perry, established a consortium of universities, hospitals, and drug developers, with the goal of positioning Texas as a leading center for psychedelic medicine research.
$29 billion for shipbuilding; $25 billion for a proposed "Golden Dome" missile defense system; $25 billion for munitions; $25 billion for various infrastructure and housing improvements. $25 billion for the U.S. Coast Guard; $16 billion for military innovation and artificial intelligence, including money for kamikaze drones, uncrewed aircraft systems, drone boats, and underwater drones; $15 billion for nuclear deterrence; and $12 billion for improving military operations in the Indo-Pacific.
=== Peru === The travelers gradually descended into the cinchona forests and former Inca territories. In Riobamba, they stayed with Montufar’s brother, where Humboldt accessed rare sixteenth-century manuscripts written in an extinct dialect and later translated into Spanish. These documents described pre-conquest events and the major eruption of Nevado de Altar volcano, which affected nearby towns with ash for seven years. Traveling from Riobamba to Cuenca across the Paramo of Azuay, Humboldt studied the remains of the Inca road, notable for its precise porphyry paving and straightness, comparable to Roman roads, leading to Cuzco. He also visited the ruins of Inca Tapayupangi’s palace and its summer house carved from rock, which offered impressive views and prompted Humboldt to admire Inca public works. Southward, the group had to ford the Rio Guancabamba, a tributary of the Amazon, twenty-seven times. Although not wide, the river’s strong current endangered their mules, which carried important collections. Humboldt described the anxiety of watching their passage. Further along, he observed the local postal system known as “el correo que nada,” where a messenger swam downstream with mail secured in a cotton handkerchief, sometimes using a balsa log to rest and stopping at huts for food and shelter. Humboldt confirmed the reliability of this system, having received mail sent this way in Paris, and noted that groups of people also traveled the river in this manner.
== Mode of action == The exact activation mechanism of Ppk1/Ppk26 ion channels in the presence of Do6a is unknown; however, it likely compares to the mode of action of endogenous peptide Vulnusin due to their similarity in structure. Vulnusin binds to Ppk/Bba channels upon mechanical injury, yet administration of this peptide independently still results in channel activation and nociceptive rolling in Drosophila larvae. This could mean that a wound in larvae tissue allows Vulnusin, normally located above the epidermal layer, to reach its receptors below epidermal cells. Do6a, delivered to Ppk/Bba receptors through a mechanical puncture of the tissue from the velvet ant sting, could elicit its response through a similar mechanism. Since Ppk1/Ppk26 ion channels are homologous to Acid-sensing ion channels (ASICs) in vertebrates, they are likely to be permeable to cations, however, the exact ion type that passes through these channels upon activation has not been determined.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.